With years of exploration in immunology and oncology, Creative Biolabs has established a comprehensive platform called OncoVirapy for oncolytic virus construction services.
Recently, oncolytic viruses (OVs) have been taking centre stage in biological therapy for cancer. Ongoing, extensive research has suggested that OVs, such as oncolytic adenovirus, herpes simplex virus, and measles virus, can be potential candidates in cancer therapy.
Considering their therapeutic efficacy and safety, as well as their low side effects, the use of such engineered viruses in biological cancer therapy has the potential to establish a milestone in cancer research.
Equipped with leading-edge technologies and platforms in this field, the scientific team at Creative Biolabs has been focusing on OVs by updating related services and completing the product list. Now, it has optimised oncolytic virus engineering and construction services to cover the whole pipeline of oncolytic immunotherapy development.
- Oncolytic Virus Engineering
Creative Biolabs provides a one-stop solution for oncolytic virus engineering, and the experienced scientists can manipulate the oncolytic virus to meet specific needs for clients’ research, preclinical studies, and drug development.
The featured services cover pathogenicity manipulation, and immunogenicity manipulation. Besides, Creative Biolabs has developed mature strategies to manipulate the oncolytic viruses, including expressing customized antibodies to increase efficacy and reduce toxicity, expressing cytokines and chemokines to enhance the anti-tumour immune response, and delivering immune checkpoint inhibitors to the tumour environment.
- Oncolytic Virus Construction
With years of exploration in immunology and oncology, Creative Biolabs has established a comprehensive platform called OncoVirapy for oncolytic virus construction services.
By virtue of the OncoVirapy platform, Creative Biolabs is able to generate the most efficacious oncolytic viral vector covering Adenovirus, Herpes Simplex Virus, Measles Virus, Vaccinia Virus, Vesicular Stomatitis Virus, and Adeno-Associated Virus, enabling wider applications in oncolytic virotherapy of cancers.
“This OncoVirapy platform can not only facilitate oncolytic virus construction but also help in other oncolytic virus development projects, such as in vitro assay for proof-of-concept study, in vivo assay for proof-of-concept study, and oncolytic virus manufacture,” as introduced by a senior scientist at Creative Biolabs, “and we will keep optimizing and expanding our services in cancer immunotherapy to meet the demand of the next generation of cancer therapy.”